| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Aminov Erez | CEO and Chairman, Director | C/O TELOMIR PHARMACEUTICALS, INC., 100 SE 2ND ST, SUITE 200 #1009, MIAMI, | /s/ Erez Aminov | 30 May 2025 | 0001986112 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TELO | Non-Qualified Options | Award | $0 | +2,000,000 | $0.000000 | 2,000,000 | 28 May 2025 | Common Stock | 2,000,000 | $2.10 | Direct | F1, F2 | |
| transaction | TELO | Restricted Stock Units (RSUs) | Award | $0 | +400,000 | $0.000000 | 400,000 | 28 May 2025 | Common Stock | 400,000 | Direct | F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 27, 2025. |
| F2 | The stock options were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options are fully vested as of the date of grant. |
| F3 | Each restricted stock unit represents a right to receive one share of Issuer's common stock. |
| F4 | The RSUs were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Plan. The RSUs are fully vested as of the date of grant. |
| F5 | Each restricted stock unit represents a right to receive one share of Issuer's common stock. |